Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aneurysmal dilatation of ductus arteriosus during lipo-prostaglandin E1 therapy for diaphragmatic hernia.

Literature DB >> 8276014

Aneurysmal dilatation of ductus arteriosus during lipo-prostaglandin E1 therapy for diaphragmatic hernia.

M Tohyama¹, A Baba, T Tsuno, K Aonuma, A Komiyama.

Abstract

We report a case of congenital diaphragmatic hernia in which aneurysmal dilatation of ductus arteriosus developed after lipo-prostaglandin E1 (PGE1) therapy for persistent fetal circulation. After surgery Lipo-PGE1 was used at a dosage of 5 ng/kg per minute from days 2-9 during which aneurysmal dilatation (7 mm in diameter) developed and remained thereafter. Ductus arteriosus ligation was then performed. Lipo-PGE1 may promote ductus arteriosus dilatation in cases of persistent fetal circulation.

Entities: Chemical Disease

Mesh：

Substances：
Alprostadil

Year: 1993 PMID： 8276014 DOI： 10.1007/bf01957520

Source DB: PubMed Journal: Eur J Pediatr ISSN： 0340-6199 Impact factor: 3.183

18 in total

1. Distribution of lipid microspheres incorporating prostaglandin E1 to vascular lesions.

Authors: Y Mizushima; T Hamano; S Haramoto; S Kiyokawa; A Yanagawa; K Nakura; M Shintome; M Watanabe
Journal: Prostaglandins Leukot Essent Fatty Acids Date: 1990-12 Impact factor: 4.006

2. Histopathology of the arterial duct (ductus arteriosus) with and without treatment with prostaglandin E1.

Authors: A C Gittenberger-de Groot; J L Strengers
Journal: Int J Cardiol Date: 1988-05 Impact factor: 4.164

3. The response of the ductus arteriosus to prostaglandins.

Authors: F Coceani; P M Olley
Journal: Can J Physiol Pharmacol Date: 1973-03 Impact factor: 2.273

4. Role of prostaglandin E1 infusion in the management of transposition of the great arteries.

Authors: L N Benson; P M Olley; R G Patel; F Coceani; R D Rowe
Journal: Am J Cardiol Date: 1979-10 Impact factor: 2.778

5. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.

Authors: Y Mizushima; Y Shiokawa; M Homma; S Kashiwazaki; Y Ichikawa; H Hashimoto; A Sakuma
Journal: J Rheumatol Date: 1987-02 Impact factor: 4.666

Aneurysmal dilatation of ductus arteriosus during lipo-prostaglandin E1 therapy for diaphragmatic hernia.

1. Distribution of lipid microspheres incorporating prostaglandin E1 to vascular lesions.

2. Histopathology of the arterial duct (ductus arteriosus) with and without treatment with prostaglandin E1.

3. The response of the ductus arteriosus to prostaglandins.

4. Role of prostaglandin E1 infusion in the management of transposition of the great arteries.

5. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.

6. Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities.

7. Palliation of cyanotic congenital heart disease in infancy with E-type prostaglandins.

8. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).

9. Histopathology of the ductus arteriosus after prostaglandin E1 administration in ductus dependent cardiac anomalies.

10. Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion.

Review 1. Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm.